

Linnea Thorlacius

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4183963/publications.pdf>

Version: 2024-02-01

17

papers

785

citations

759233

12

h-index

888059

17

g-index

19

all docs

19

docs citations

19

times ranked

636

citing authors

#	ARTICLE	IF	CITATIONS
1	Sub-classification of Hidradenitis suppurativa: a cross-sectional study. <i>Archives of Dermatological Research</i> , 2022, 314, 207-212.	1.9	4
2	Development and initial validation of the <scp>HSâ€¢IGA</scp> : a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials*. <i>British Journal of Dermatology</i> , 2022, 187, 203-210.	1.5	8
3	Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa*. <i>British Journal of Dermatology</i> , 2021, 184, 681-687.	1.5	15
4	How to diagnose and measure primary hyperhidrosis: a systematic review of the literature. <i>Clinical Autonomic Research</i> , 2021, 31, 511-528.	2.5	8
5	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	1.2	165
6	The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. <i>British Journal of Dermatology</i> , 2020, 183, 340-348.	1.5	52
7	Severity staging of hidradenitis suppurativa: is Hurley classification the answer?. <i>British Journal of Dermatology</i> , 2019, 181, 243-244.	1.5	5
8	Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument. <i>Skin Appendage Disorders</i> , 2019, 5, 221-229.	1.0	22
9	Interâ€¢rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2019, 181, 483-491.	1.5	50
10	A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. <i>British Journal of Dermatology</i> , 2018, 179, 642-650.	1.5	119
11	Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. <i>British Journal of Dermatology</i> , 2018, 179, 182-185.	1.5	63
12	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTÓRIC consensus meetings I and II. <i>British Journal of Dermatology</i> , 2018, 178, 715-721.	1.5	33
13	Increased Suicide Risk in Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2018, 138, 52-57.	0.7	134
14	Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017, 7, e014733.	1.9	37
15	A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark. <i>British Journal of Dermatology</i> , 2017, 176, 1083-1085.	1.5	38
16	Distinguishing hyperhidrosis and normal physiological sweat production: new data and review of hyperhidrosis data for 1980â€“2013. <i>International Journal of Dermatology</i> , 2015, 54, e409-15.	1.0	22
17	Idiopathic Localised Unilateral Hyperhidrosis in a 7-year-old Girl: A Case Report. <i>Acta Dermato-Venereologica</i> , 2015, 95, 364-365.	1.3	0